Cargando…
The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neurotoxic oncolytic virus that is effective for the treatment of malignant glioblastoma and ovarian cancer. Here, we evaluate the therapeutic efficacy of VSV-GP for malignant melanoma. All of the human,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869501/ https://www.ncbi.nlm.nih.gov/pubmed/29498639 http://dx.doi.org/10.3390/v10030108 |
_version_ | 1783309296545562624 |
---|---|
author | Kimpel, Janine Urbiola, Carles Koske, Iris Tober, Reinhard Banki, Zoltan Wollmann, Guido von Laer, Dorothee |
author_facet | Kimpel, Janine Urbiola, Carles Koske, Iris Tober, Reinhard Banki, Zoltan Wollmann, Guido von Laer, Dorothee |
author_sort | Kimpel, Janine |
collection | PubMed |
description | Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neurotoxic oncolytic virus that is effective for the treatment of malignant glioblastoma and ovarian cancer. Here, we evaluate the therapeutic efficacy of VSV-GP for malignant melanoma. All of the human, mouse, and canine melanoma cell lines that were tested, alongside most primary human melanoma cultures, were infected by VSV-GP and efficiently killed. Additionally, we found that VSV-GP prolonged the survival of mice in both a xenograft and a syngeneic mouse model. However, only a few mice survived with long-term tumor remission. When we analyzed the factors that might limit VSV-GP’s efficacy, we found that vector-neutralizing antibodies did not play a role in this context, as even after eight subsequent immunizations and an observation time of 42 weeks, no vector-neutralizing antibodies were induced in VSV-GP immunized mice. In contrast, the type I IFN response might have contributed to the reduced efficacy of the therapy, as both of the cell lines that were used for the mouse models were able to mount a protective IFN response. Nevertheless, early treatment with VSV-GP also reduced the number and size of lung metastases in a syngeneic B16 mouse model. In summary, VSV-GP is a potent candidate for the treatment of malignant melanoma; however, factors limiting the efficacy of the virus need to be further explored. |
format | Online Article Text |
id | pubmed-5869501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58695012018-03-28 The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma Kimpel, Janine Urbiola, Carles Koske, Iris Tober, Reinhard Banki, Zoltan Wollmann, Guido von Laer, Dorothee Viruses Article Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neurotoxic oncolytic virus that is effective for the treatment of malignant glioblastoma and ovarian cancer. Here, we evaluate the therapeutic efficacy of VSV-GP for malignant melanoma. All of the human, mouse, and canine melanoma cell lines that were tested, alongside most primary human melanoma cultures, were infected by VSV-GP and efficiently killed. Additionally, we found that VSV-GP prolonged the survival of mice in both a xenograft and a syngeneic mouse model. However, only a few mice survived with long-term tumor remission. When we analyzed the factors that might limit VSV-GP’s efficacy, we found that vector-neutralizing antibodies did not play a role in this context, as even after eight subsequent immunizations and an observation time of 42 weeks, no vector-neutralizing antibodies were induced in VSV-GP immunized mice. In contrast, the type I IFN response might have contributed to the reduced efficacy of the therapy, as both of the cell lines that were used for the mouse models were able to mount a protective IFN response. Nevertheless, early treatment with VSV-GP also reduced the number and size of lung metastases in a syngeneic B16 mouse model. In summary, VSV-GP is a potent candidate for the treatment of malignant melanoma; however, factors limiting the efficacy of the virus need to be further explored. MDPI 2018-03-02 /pmc/articles/PMC5869501/ /pubmed/29498639 http://dx.doi.org/10.3390/v10030108 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kimpel, Janine Urbiola, Carles Koske, Iris Tober, Reinhard Banki, Zoltan Wollmann, Guido von Laer, Dorothee The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title_full | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title_fullStr | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title_full_unstemmed | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title_short | The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma |
title_sort | oncolytic virus vsv-gp is effective against malignant melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869501/ https://www.ncbi.nlm.nih.gov/pubmed/29498639 http://dx.doi.org/10.3390/v10030108 |
work_keys_str_mv | AT kimpeljanine theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT urbiolacarles theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT koskeiris theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT toberreinhard theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT bankizoltan theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT wollmannguido theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT vonlaerdorothee theoncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT kimpeljanine oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT urbiolacarles oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT koskeiris oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT toberreinhard oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT bankizoltan oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT wollmannguido oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma AT vonlaerdorothee oncolyticvirusvsvgpiseffectiveagainstmalignantmelanoma |